The Latest Cardiac and Vascular News
Echocardiographic Data Show Treatment with Aficamten for 10 Weeks Results In Improved Cardiac Structure, Myocardial Relaxation and Mitral Valve Mechanics SOUTH SAN FRANCISCO, Calif., June 13, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data from a new analysis of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM) […]
SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 31, 2022 it granted stock options to purchase an aggregate of 179,100 shares of common stock to 23 new employees, whose employment commenced in May 2022, as a material inducement to […]
FDA Plans to Convene Advisory Committee Meeting SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the Company recently participated in a mid-cycle communication meeting with the U.S. Food & Drug Administration (FDA) and was informed that the Agency plans to convene an […]
No Effect of Omecamtiv Mecarbil On Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction in METEORIC-HF Healthcare Resource Utilization and Cost Analysis from GALACTIC-HF Demonstrate Treatment with Omecamtiv Mecarbil Led to 19% Cost Reduction Per Patient in Key Subgroup Additional Results from GALACTIC-HF Indicate Treatment with Omecamtiv […]
Cohort 4 to Enroll Patients with Non-Obstructive Hypertrophic Cardiomyopathy SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the opening of enrollment in Cohort 4 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), an ongoing Phase 2 clinical trial of aficamten, an investigational next-generation cardiac […]
SOUTH SAN FRANCISCO, Calif., March 01, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 28, 2022 it granted stock options to purchase an aggregate of 86,850 shares of common stock to eight new employees, whose employment commenced in February 2022, as a material inducement to […]
Commercial Launch Readiness Activities Underway for Omecamtiv Mecarbil in Advance of PDUFA Date of November 30, 2022 SEQUOIA-HCM Open to Enrollment; Development Program for Aficamten Expanding in 2022 Company Provides 2022 Financial Guidance; More Than 2 Years of Cash Runway SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) — Cytokinetics, […]
Pivotal Trial to Assess the Potential of Aficamten to Improve Exercise Capacity, Heart Failure Symptoms and Functional Class SOUTH SAN FRANCISCO, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), a Phase 3 clinical trial of aficamten in patients with symptomatic obstructive […]
SOUTH SAN FRANCISCO, Calif. and OAKLAND, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) and the American Heart Association (AHA) Bay Area today announced a three-year collaboration to accelerate education and awareness of heart disease. Within the collaboration, Cytokinetics will provide funding and support for several initiatives […]
No Effect of Omecamtiv Mecarbil On Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction Results Will Be Presented in Late Breaking Clinical Trial Session at the American College of Cardiology 71st Annual Scientific Session & Expo NDA for Omecamtiv Mecarbil Recently Accepted for Review by FDA Based on Results of […]
